Laura Taylor
Nurse Practitioner · Fort Myers, FLNPI 1073827010
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,536 of the $27,153 with a category attached, or 64.6%. 29 manufacturers reported payments, led by AbbVie at 43.3% of the total. 2025 is the largest year on record at $14,266, 4.4 times the $3,207 reported in 2021. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 948 payments — averaging $28.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Johnson & Johnson$5K
- Sanofi$1K
- Novartis$1K
- UCB, Inc.$1K
- Amgen$979
- plus $6K from 23 others
What the payments were for
- Consulting fees$1,5006%
- Speaking & faculty fees$6,07522%
- Travel & lodging$1,7757%
- Food & beverage$17,53665%
- Education$2681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 263 | $11,744 |
| Johnson & Johnson | 178 | $4,694 |
| Sanofi | 39 | $1,175 |
| Novartis | 71 | $1,170 |
| UCB, Inc. | 40 | $1,041 |
| Amgen | 58 | $979 |
| Sun Pharmaceutical Industries Inc. | 49 | $933 |
| Regeneron Healthcare Solutions, Inc. | 19 | $644 |
| Lilly USA, LLC | 26 | $592 |
| Pfizer | 36 | $592 |
| Incyte Corporation | 17 | $480 |
| LEO Pharma Inc. | 20 | $473 |
| E.r. Squibb & Sons, L.L.C. | 32 | $428 |
| Arcutis Biotherapeutics, Inc. | 17 | $316 |
| Galderma Laboratories, L.p. | 10 | $310 |
| Mayne Pharma Commercial LLC | 19 | $296 |
| Almirall LLC | 9 | $205 |
| Boehringer Ingelheim | 8 | $202 |
| EPI Health, LLC | 10 | $180 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $175 |
| VYNE Pharmaceuticals Inc. | 4 | $135 |
| Verrica Pharmaceuticals Inc. | 1 | $125 |
| Dermavant Sciences, Inc. | 5 | $100 |
| Organon | 5 | $44 |
| Mylan Institutional Inc. | 2 | $37 |
| Strata Skin Sciences, Inc. | 1 | $27 |
| Merz North America, Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $19 |
| Journey Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,153 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 63 | $1,334,531 |
| OtezlaApremilast | 48 | $270,704 |
| Dupixent PenDupilumab | 72 | $266,205 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 33 | $259,664 |
| Taltz AutoinjectorIxekizumab | 36 | $244,868 |
| Humira(Cf) PenAdalimumab | 27 | $176,615 |
| Enbrel MiniEtanercept | 12 | $103,968 |
| Dupixent SyringeDupilumab | 17 | $61,377 |
| Clobetasol Propionate | 200 | $7,264 |
| Betamethasone Dipropionate | 203 | $7,116 |
| Tacrolimus | 21 | $3,677 |
| Triamcinolone Acetonide | 232 | $3,204 |
| Metronidazole | 43 | $2,377 |
| Ketoconazole | 153 | $2,274 |
| Doxycycline Hyclate | 84 | $1,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $979 | $270,70448 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Fort Myers
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
- Jennifer PuleoTampa$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.